-
COST-EFFECTIVENESS ANALYSIS OF DURVALUMAB AS FIRST-LINE TREATMENT FOR NON-SMALL CELL LUNG CANCER IN JAPAN
Aug 11, 2026, 15:45 PM -
COST-EFFECTIVENESS OF COLORECTAL CANCER SCREENING STRATEGIES IN LOW- AND MIDDLE-INCOME COUNTRIES: A SYSTEMATIC REVIEW AND META-ANALYSIS
Aug 11, 2026, 15:45 PM -
CROSS-AGENCY APPRAISAL OF REAL-WORLD EVIDENCE IN ONCOLOGY AND RARE DISEASE DRUG-INDICATION HTA APPRAISALS ACROSS SELECT APAC MARKETS AND ENGLAND: A COMPARATIVE HTA APPRAISAL REVIEW (2021-2026)
Aug 11, 2026, 15:45 PM -
IS THE U.S. MOST FAVORED NATION (MFN) INITIATIVE EXPECTED TO AFFECT DRUG LAUNCHES IN KOREA...
Aug 11, 2026, 15:45 PM -
LARGE LANGUAGE MODEL-EXTRACTED CLINICAL FEATURES ENHANCED STRUCTURED ELECTRONIC MEDICAL RECORDS DATA FOR PREDICTING TREATMENT RESPONSE DEPTH IN MULTIPLE MYELOMA
Aug 11, 2026, 15:45 PM -
THE COST-EFFECTIVENESS OF USING PIVKA-II IN COMBINATION WITH ULTRASOUND-AFP IN DETECTING HEPATOCELLULAR CARCINOMA
Aug 11, 2026, 15:45 PM -
ARTIFICIAL INTELLIGENCE APPLICATIONS IN HEALTH TECHNOLOGY ASSESSMENT ACROSS ASIA-PACIFIC: A TARGETED REVIEW OF USE CASES, ADOPTION BARRIERS, AND OPPORTUNITIES
Aug 11, 2026, 15:45 PM -
CLINICAL, HUMANISTIC, AND HEALTHCARE RESOURCE UTILIZATION BURDEN OF SICKLE CELL DISEASE IN INDIA: INSIGHTS FROM THE ASCRIBE STUDY
Aug 11, 2026, 15:45 PM -
IMPACT OF NATIONAL HEALTH INSURANCE REIMBURSEMENT GUIDELINE REVISION ON HUMAN SERUM ALBUMIN UTILIZATION: AN INTERRUPTED TIME SERIES ANALYSIS USING NHIS-NSC DATA
Aug 11, 2026, 15:45 PM -
AI-ASSISTED CLINICAL DECISION SUPPORT FOR RARE DISEASE DIAGNOSIS: EVIDENCE FROM CHINA'S FIRST DISEASE-SPECIFIC LARGE LANGUAGE MODEL AND REAL-WORLD PHYSICIAN ADOPTION DATA
Aug 11, 2026, 15:45 PM -
COMPARATIVE EFFICACY AND SAFETY OF FIRST-LINE ALK INHIBITORS FOR ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER: A SYSTEMATICREVIEW AND NETWORK META-ANALYSIS...
Aug 11, 2026, 15:45 PM -
IMPLEMENTATION GAPS IN CERVICAL CANCER PREVENTION: PERSPECTIVES OF HEALTHCARE PROFESSIONALS IN NORTH SULAWESI, INDONESIA
Aug 11, 2026, 15:45 PM -
EVALUATING THE HOLISTIC VALUE OF INNOVATIVE THERAPIES VIA THE TREATMENT IMPACT MODEL: A CASE STUDY ON EMICIZUMAB FOR HAEMOPHILIA A IN SINGAPORE
Aug 11, 2026, 15:45 PM -
PROVIDER STRATEGIC RESPONSES TO A BLENDED HOSPITAL PAYMENT REFORM IN CHINA: EVIDENCE ON PATIENT SELECTION, SERVICE ADJUSTMENT, AND PRICE MANIPULATION...
Aug 11, 2026, 15:45 PM -
REAL-WORLD COST-UTILITY EVIDENCE SUPPORTING ORAL HEALTH INTEGRATION IN DIABETES CARE IN CHILE
Aug 11, 2026, 15:45 PM -
AI-SUPPORTED PRE-MORTEM ANALYSIS FOR HEOR STRATEGIES: LESSONS FROM PROJECT MANAGEMENT SCIENCE OBJECTIVES
Aug 11, 2026, 15:45 PM -
A PREDICTION MODEL FOR CHRONIC KIDNEY DISEASE PROGRESSION...
Aug 11, 2026, 15:45 PM -
THE ROLE OF CONSUMER COMMENTS IN PBAC RECOMMENDATIONS: INSIGHTS FROM AUSTRALIAN HTA DECISIONS (2020-2025)
Aug 11, 2026, 15:45 PM -
COST-UTILITY OF FIRST-LINE SYSTEMIC THERAPIES FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA IN VIETNAM: A PRELIMINARY ANALYSIS
Aug 11, 2026, 15:45 PM -
ASSOCIATION OF SOCIAL ISOLATION, HEALTHY LIFESTYLE, AND ALL-CAUSE MORTALITY AMONG RURAL OLDER ADULTS: JOINT EXPOSURE AND MEDIATION ANALYSES
Aug 11, 2026, 15:45 PM
